Pontine Glioma - Pipeline Review, H1 2020

May 2020 | 469 pages | ID: P9D9709DBFAEN
Global Markets Direct

Abstracts

Pontine Glioma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma – Pipeline Review, H1 2020, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.

Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 16, 12, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 3, 1 and 1 molecules, respectively.

Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Pontine Glioma - Overview
Pontine Glioma - Therapeutics Development
Pontine Glioma - Therapeutics Assessment
Pontine Glioma - Companies Involved in Therapeutics Development
Pontine Glioma - Drug Profiles
Pontine Glioma - Dormant Projects
Pontine Glioma - Discontinued Products
Pontine Glioma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Pontine Glioma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pontine Glioma - Pipeline by Accendatech Au Pty Ltd, H1 2020
Pontine Glioma - Pipeline by Adastra Pharmaceuticals Inc, H1 2020
Pontine Glioma - Pipeline by Apexigen Inc, H1 2020
Pontine Glioma - Pipeline by Bayer AG, H1 2020
Pontine Glioma - Pipeline by Bexion Pharmaceuticals LLC, H1 2020
Pontine Glioma - Dormant Projects, H1 2020
Pontine Glioma - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Pontine Glioma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Accendatech Au Pty Ltd
Adastra Pharmaceuticals Inc
Apexigen Inc
Bayer AG
Bexion Pharmaceuticals LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
CDG Therapeutics Inc
Curis Inc
DelMar Pharmaceuticals Inc
DNAtrix Inc
Eli Lilly and Co
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd
Kazia Therapeutics Ltd
Lumos Pharma Inc
M4K Pharma Inc
Mana Therapeutics Inc
Medicenna Therapeutics Corp
Midatech Pharma Plc
Moleculin Biotech LLC
Novartis AG
Noxopharm Ltd
Oncoceutics Inc
OncoRx Pharmaceuticals Inc
Oncotelic Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
Regeneron Pharmaceuticals Inc
Secura Bio Inc
Shionogi & Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Tmunity Therapeutics Inc
Xcovery Holding Co LLC
Y-mAbs Therapeutics Inc
ZIOPHARM Oncology Inc